Trial Profile
A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB
- 19 Sep 2006 New trial record.